Neuphoria Therapeutics Inc (NEUP)

NASDAQ
Currency in USD
4.7100
-0.0600(-1.26%)
Closed
After Hours
4.7700+0.0600(+1.27%)
NEUP Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 10 days
Fair Value
Day's Range
4.50005.0523
52 wk Range
2.124016.0800
Key Statistics
Edit
Prev. Close
4.69
Open
4.75
Day's Range
4.5-5.0523
52 wk Range
2.124-16.08
Volume
61.84K
Average Vol. (3m)
564.37K
1-Year Change
-59.79%
Book Value / Share
0.01
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NEUP Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
21.0000
Upside
+345.86%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week
Show more

Neuphoria Therapeutics Inc Company Profile

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders; and Nav1.7/1.8 inhibitors which is in preclinical trial for the potential treatment of chronic pain without the liability of addiction associated with opioid treatment. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer’s disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.

Compare NEUP to Peers and Sector

Metrics to compare
NEUP
Peers
Sector
Relationship
P/E Ratio
−0.7x−4.9x−0.6x
PEG Ratio
−0.010.130.00
Price / Book
0.4x2.9x2.6x
Price / LTM Sales
-25.8x3.1x
Upside (Analyst Target)
346.8%130.2%48.2%
Fair Value Upside
Unlock1.9%8.0%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 21.0000
(+345.86% Upside)

Earnings

Latest Release
Nov 27, 2024
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

4.250
NVNI
+1.67%
3.030
VNCE
-10.36%
1.45
STAI
0.00%
19.4300
NUKK
-9.42%

FAQ

What Is the Neuphoria Therapeutics (NEUP) Stock Price Today?

The Neuphoria Therapeutics stock price today is 4.71

What Stock Exchange Does Neuphoria Therapeutics Trade On?

Neuphoria Therapeutics is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Neuphoria Therapeutics?

The stock symbol for Neuphoria Therapeutics is "NEUP."

What Is the Neuphoria Therapeutics Market Cap?

As of today, Neuphoria Therapeutics market cap is 7.63M.

What is Neuphoria Therapeutics Earnings Per Share?

The Neuphoria Therapeutics EPS is -0.005.

What Is the Next Neuphoria Therapeutics Earnings Date?

Neuphoria Therapeutics will release its next earnings report on Feb 20, 2025.

From a Technical Analysis Perspective, Is NEUP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.